Table 3.
Median overall and disease-free survival times and hazard ratios in the patient subgroups as a function of PRKCA overexpression.Abbreviations: PRKCA, protein kinase C alpha; UV, univariate; MV, multivariate; HR, hazard ratio; CI, confidence interval; OS, overall survival; DFS, disease-free survival; TU, tumor; LFU, last follow-up; undef., undefined.
| Cohort | Median Survival a (Months) | UV HR (95% CI) | UV p-Value c | MV HR (95% CI) | MV p-Value d | |
|---|---|---|---|---|---|---|
| PRKCA positive b | PRKCA negative | |||||
| Vienna All OS | 15 | 130 | 34.34 (4.15–284.1) | 0.001 | - | - |
| Vienna Young OS | 15 | Undef. a | 141.8 (12.24–1642) | <0.001 | - | - |
| Vienna All DFS | 0.5 | Undef. a | 107.7 (10.03–1158) | <0.001 | - | - |
| Vienna Young DFS | 0.5 | Undef. a | 31.15 (3.56–272.7) | 0.002 | - | - |
| Vienna All TU at LFU | 15 | Undef. a | 53.07 (5.82–483.9) | <0.001 | - | - |
| Vienna Young TU at LFU | 15 | 94 | 44.25 (4.87–401.9) | <0.001 | - | - |
| TCGA DFS All | Undef. a | Undef. a | 0.58 (0.14–2.47) | 0.46 | - | - |
| TCGA OS All | Undef. a | 52.27 | 1.51 (0.38–5.95) | 0.56 | - | - |
| TCGA OS Young | 10.74 | Undef. a | 3.2 (0.47–21.6) | 0.23 | - | - |
| TCGA DFS Young | 6.83 | Undef. a | 16.5 (1.69–161.2) | 0.02 | - | - |
| Combined OS All | 21 | 90.05 | 3.62 (1.18–11.45) | 0.02 | 3.57 (1.53–8.56) |
< 0.01 |
| Combined DFS All | 13 | Undef. a | 2.82 (0.78–10.10) | 0.11 | 1.68 (0.25–13.23) |
0.55 |
| Combined OS Young | 10.75 | Undef. a | 18.95 (4.03–88.87) | <0.001 | - | - |
| Combined DFS Young | 2.17 | Undef. a | 29.65 (5.96–147.40) | <0.001 | - | - |
a by definition Kaplan–Meier estimates of median survival cannot be computed in groups where <50% of individuals have reached the statistical endpoint (death) within the period of observation, b overexpression was defined as IHC score ≥ 4 in the Vienna cohort and as a z-score ≥1.96 in the TCGA cohort, c determined by log rank test, d determined by Cox regression analysis.